



ABIVAX STRENGTHENS EXECUTIVE MANAGEMENT TEAM WITH SENIOR APPOINTMENTS

October 30, 2014

Details

Published on Thursday, 30 October 2014 13:40

**Karl Birsthite, M.D., appointed VP of Global Regulatory Affairs
Daniel Kenny appointed Chief Commercial Officer & VP of Business Development**

Paris, October 30th, 2014 – ABIVAX, the Paris-based clinical stage biopharmaceutical company specialised in the development and commercialisation of therapeutic vaccines and anti-viral compounds, today announced the appointments of Karl Birsthite, M.D., and Daniel Kenny to its Executive Management team as VP of Global Regulatory Affairs and Chief Commercial Officer & VP of Business Development, respectively.

ABIVAX is establishing itself as a world leader in specialty vaccine and anti-viral drug development to combat infectious and malignant diseases, by developing a number of innovative therapeutic vaccines and antivirals, including clinical stage products ABX203 therapeutic vaccine against chronic hepatitis B and the antiviral ABX464 against HIV.

These two senior appointments further strengthen the Executive Management team led by Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX and supported by both the Board of Directors and the Company's Scientific Advisory Board.

Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX, said: "ABIVAX is a highly ambitious company that is utilising novel cutting edge science together with strategic partnerships to develop novel therapeutic vaccines and anti-viral drugs. This will allow us to reduce the human suffering and economic impact of some of the most important infectious diseases faced by the world today. Karl and Daniel, with whom I have been fortunate to have worked with in the past, are recognised industry leaders in their respective fields, reinforcing the strength of the ABIVAX world-class Executive Team."